Translational Development Acquisition Corp.

Translational Development Acquisition Corp., whose warrants trade on the public markets under the ticker TDACW, filed an amended annual report on Form 10-K/A with the SEC on May 11, 2026, bearing accession number 0001104659-26-058544. The blank-check company is focused on the healthcare and life sciences sector, as signaled by its name's reference to translational medicine — the discipline bridging laboratory discovery and clinical application. The amended filing indicates an active regulatory record for the vehicle as it pursues or refines its combination strategy. Sponsor details and IPO vintage were not disclosed in the filed document reviewed here. For complete sponsor data, deal timelines, and filing history on Translational Development Acquisition Corp. and the full SPAC universe, sign up for full data access at SpacDesk.